Meda buys Acton for $135M+, snags asthma inhaler

Swedish pharmaceutical company Meda bought Massachusetts-based Acton Pharmaceuticals, the maker of a new asthma drug-device combo, for more than $135 million plus milestone payments. The inhaler, Aerospan, which delivers the corticosteroid flunisolide, is the only FDA-approved inhaler in its class to incorporate a built-in spacer device, which helps control the delivery of the drug to the lung, according to the company. On top of the agreed-upon upfront payment, Meda offered milestone payments of more than $10 million. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.